Bluebird bio has announced a restructuring to cut costs by 20% and achieve quarterly cash flow break-even by late 2025. The ...

Wave Life Sciences has announced positive interim data from the ongoing Phase II FORWARD-53 study of WVE-N531, which is an ...

Biomedicines (Generate) today announced a multi-target collaboration with Swiss pharm giant Novartis to discover and develop ...

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved Otsuka’s Lupkynis (voclosporin) for lupus nephritis ...

CSL Vifor today announced that Japan’s Ministry of Health and Labor Welfare (MHLW) has granted its partner, Zeria ...

Research and Manufacturers of America (PhRMA) has taken its legal challenge against the US government’s drug pricing reforms ...

BioAtla has granted Context Therapeutics an exclusive global license for BA3362, a T cell-engaging antibody targeting solid ...

Japanese drugmaker Eisai closed down 2.3% at 5,587 yen today, despite news of regulatory approvals for two of its drugs.

Daiichi Sankyo and AstraZeneca saw a dip in stock prices after announcing that their Phase III TROPION-Breast01 trial for ...

In a news packed morning, Japanese drugmaker Astellas Pharma (TYO: 4503) today revealed two regulatory approvals.

Takeda has received Japanese approval for Fruzaqla (fruquintinib) to treat advanced or recurrent colorectal cancer (CRC) that ...

Belgian drugmaker UCB and US biotech Biogen have announced positive top-line results from the Phase III PHOENYCS GO study ...